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Abstract  
As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence 
(NICE) invited the manufacturer of vedolizumab (Takeda UK) to submit evidence of the clinical effectiveness 
and cost-effectiveness of vedolizumab for the treatment of patients with moderate-to-severe active ulcerative 
colitis (UC).  The Evidence Review Group (ERG) produced a critical review of the evidence for the clinical 
effectiveness and cost-effectiveness of the technology, based upon the company¶V VXEPLVVLRQ WR 1,&( 7KH
evidence was derived mainly from the GEMINI1 trial, which is a Phase III, multicentre, randomised, double-
blind, placebo-controlled trial designed to evaluate the efficacy and safety of vedolizumab as an induction and 
maintenance treatment in patients with moderate-to-severe active UC who had an inadequate response to, loss of 
response to, or intolerance to conventional therapy or anti-Tumour necrosis factor-alpha (TNF-Į. The clinical 
evidence showed that vedolizumab performed significantly better than placebo in both the induction and 
maintenance phases.  In the post-hoc subgroup analyses, patients with or without prior anti-TNF-Į WKHUDS\, 
vedolizumab performed better then placebo (p-value not reported).  In addition, a greater improvement in 
health-related quality of life was observed in patients treated with vedolizumab and the frequency and types of 
adverse events were similar between the vedolizumab and placebo group but the evidence was limited to short-
term follow-up. There were a number of limitations and uncertainties in the clinical evidence base which 
warrant caution in its interpretation.  In particular, the post-hoc subgroup analyses and high dropout rates in the 
maintenance phase of the GEMINI1 trial.  The company also presented a network meta-analysis of vedolizumab 
versus other biologics therapies indicated for moderate-to-severe UC. However, the ERG considered that the 
results presented may have underestimated the uncertainty in treatment effects since fixed effects models were 
used, despite clear evidence of heterogeneity amongst the trials included in the network. Results from the 
company¶s economic evaluation (which included price reductions to reflect the proposed Patient Access Scheme 
for vedolizumab) suggested that vedolizumab is the most effective option compared with surgery and 
conventional therapy in the following three populations: (i) mix intention to treat population, including patients 
who have previously received anti-TNF-Į WKHUDS\ DQG WKRVH ZKRDUH DQWi-TNF-ĮQDwYH LL) patients who are 
anti-TNF-Į QDwYH RQO\ DQG LLL) patients who have previously failed anti-TNF-Į WKHUDS\ RQO\. The ERG 
concluded that the results of the company¶V HFRQRPLF HYDOXDWLRQ FRXOG QRW EH FRQVLGHUHG UREXVW EHFDXVH RI
errors in model implementation, the omission of relevant comparators, deviations from the NICE Reference 
Case and questionable model assumptions. The ERG amended the company¶V PRGHO DQG GHPRQVWUDWHG WKDW
vedolizumab is expected to be dominated by surgery in all three populations. 
 
 
Key Points for Decision Makers 
x Vedolizumab appears to be more effective in both the induction and maintenance phase compared with 
placebo in patients with moderate-to-severe active ulcerative colitis who have had an inadequate 
response to, loss of response to, or intolerance to conventional therapy or TNF-Įinhibitor.  However, 
the subgroup analyses for patients with or without prior TNF-ĮLQKLELWRUWKHUDS\ZHUHpost-hoc and the 
study was not powered for these assessments. 
x The findings of the network meta-analysis of vedolizumab versus TNF-Įinhibitor are limited due to a 
number of uncertainties in treatment effects.  In addition, there is currently no head-to-head randomised 
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controlled trial comparing vedolizumab to other biologic therapies indicated for moderate-to-severe 
ulcerative colitis. 
x The National Institute for Health and Care Excellence (NICE) Appraisal Committee recommended 
vedolizumab within its licence indication but only if the company provides vedolizumab with the 
discount agreed in the patient access scheme. 
 
 
1. Introduction 
Health technologies must be shown to be clinically effective and to represent a cost-effective use of National 
Health Service (NHS) resources in order to be recommended for use within the NHS in England and Wales. The 
National Institute for Health and Care Excellence (NICE) is an independent organisation responsible for 
providing national guidance on promoting good health and preventing and treating ill health in priority areas 
with significant impact. The NICE single technology appraisal (STA) process usually covers new technologies 
within a single indication, soon after they have received UK marketing authorisation [1]. Within the STA 
process, the company provides NICE with a written submission which summarises the company¶VHVWimates of 
the clinical effectiveness and cost-effectiveness of the technology, together with an executable health economic 
model. This submission is reviewed by an external organisation independent of NICE (the Evidence Review 
Group [ERG]), which consults with clinical specialists and produces an ERG report. After consideration of the 
company¶VVXEPLVVLRQWKH(5*UHSRUWDQGWHVWLPRQ\IURPH[SHUWVDQGRWKHUVWDNHKROGHUVWKH1,&($SSUDLVDO
Committee formulates the preliminary guidance, the Appraisal Consultation Document (ACD), which indicates 
the initial decision on whether or not to recommend the intervention.  Stakeholders are then invited to comment 
on the submitted evidence and the ACD, after which a subsequent ACD may be produced or a Final Appraisal 
Determination (FAD) is issued, which is open to appeal. An ACD is not produced when the intervention is 
recommended without restriction; in that instance, a FAD is produced directly. 
 
This paper presents a summary of the ERG report [2] for the STA of vedolizumab for the treatment of adults 
with moderate-to-severe active ulcerative colitis (UC) and the subsequent development of the NICE guidance 
for the use of this drug in England and Wales. Full details of all relevant appraisal documents, can be found on 
the NICE website [3].  
 
 
2. The Decision Problem  
UC is a relapsing-remitting form of inflammatory bowel disease (IBD) [4] with inflammation typically 
occurring in the colon and rectum. Symptoms include the development of bloody diarrhoea with or without 
mucus, abdominal pain, weight loss, fatigue, rectal urgency and tenesmus [5-7]. The onset of symptoms and 
diagnosis of UC usually occurs in young-middle aged working adults. Peak incidence is between 15 and 25 
years of age, with a potential second peak between 55 and 65 years [8].  Over two-thirds of patients describe 
interference with work and three-quarters describe interference with leisure activities [9]. The unpredictable 
nature of relapse in UC DQGWKHVLJQLILFDQWV\PSWRPEXUGHQDOVRKDVDQHJDWLYHHIIHFWRQSDWLHQWV¶SV\FKRORJLFDO
well-being and quality of life [10].  UC is recognised as the most common form of IBD in the UK. The 
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incidence of UC is approximately 10 per 100,000 population per year, whilst the prevalence of the disease is 
approximately 240 per 100,000 population [8].  The majority (approximately 80%) of incident cases are 
reported to be of mild or moderate severity.  An estimated 132,600 people in England and Wales have been 
diagnosed with UC [8]. 
 
 
2.1 Current Treatment 
At present, there is no agreed pathway for the management of patients with treatment refractory (second-line 
conventional therapy) moderate-to-severe active UC. The main aim of treatment is to resolve symptoms and 
maintain remission.  Conventional therapy for UC may include aminosalicylates (mesalamine, sulfasalazine, 
balsalazide and olsalazine), corticosteroids (beclomethasone, or prednisolone), thiopurines (mercaptopurine or 
azathioprine) and calcineurin inhibitors. Tumour necrosis factor-alpha (TNF-Į) inhibitors (infliximab, 
adalimumab and golimumab) may be used for disease refractory to conventional therapy [8].  Choice of 
treatment may be influenced by the severity of symptoms, the extent and location of inflammation, and is based 
on clinical expertise and individual patient choice.  Patients who fail both conventional and TNF-Į LQKLELWRU 
therapy typically have no other medical therapeutic options available to them and up to 40% [11]  may progress 
to surgery [12].   However, people may be reluctant to consider surgery due to the potential serious post-surgery 
complications such as bleeding, faecal incontinence, depression, distorted body image, sexual dysfunction, 
female infertility, pouchitis, pouch leakage, pelvic abscesses, pouch fistulae, small bowel obstruction and 
anastomotic stricture [13]. Current treatment options are also associated with safety concerns associated with 
long term use of corticosteroids, immunomodulators and TNF-Į inhibitors including immunosuppression, 
osteoporosis and lymphoma [14;15]. 
 
Vedolizumab ((Entyvio®) 7DNHGD LV D KXPDQLVHG PRQRFORQDO DQWLERG\ ,W WDUJHWV Įȕ LQWHJULQ ZKLFK LV
H[SUHVVHGLQFHUWDLQZKLWHEORRGFHOOVWKDWDUHIRXQGLQWKHJXWĮȕLQWHJULQLVUHVSRQVLEOHIRUUHFUXLWLQJWKHVH
cells to inflamed bowel tissue. Vedolizumab therefore offers gut-selective targeted therapy without systemic 
immunosuppression. On 22 May 2014, the European Medicines Agency (EMA) [16] granted marketing 
authorisation for the medicinal product Entyvio ³for the treatment of adult patients with moderate-to-severe 
active UC who have had an inadequate response with, or lost response to, or were intolerant to either 
conventional therapy or a TNF-Į LQKLELWRU. The recommended dosage of vedolizumab is 300 mg given by 
intravenous infusion at 0, 2 and 6 weeks and then every 8 weeks thereafter. Continued therapy for people with 
UC should be carefully reconsidered if no evidence of therapeutic benefit is observed by week 10.  Some 
patients with decreased response may benefit from an increase in dosing frequency to 300mg every four weeks.´ 
 
NICE issued a final scope [17] in June 2014 to appraise the clinical effectiveness and cost-effectiveness of 
vedolizumab, within its licensed indication, for the treatment of moderate-to-severe active UC in adults who are 
intolerant of, or whose disease has had an inadequate response or loss of response to conventional therapy or a 
TNF-Įinhibitor. 
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3. The Independent Evidence Review Group Review 
The company (Takeda UK) provided a submission to NICE on the clinical and cost-effectiveness of 
vedolizumab for the treatment of patients with moderate-to-severe active UC [3;18].  The ERG critically 
reviewed the evidence presented in the company¶V VXEPLVVLRQ E\ DVVHVVLQJ L ZKHWKHU WKH VXEPLVVLRQ
conformed to NICE methodological guidelines; (ii) whether the company¶V LQWHUSUHWDWLRQ DQG DQDO\VLV RI WKH
evidence were appropriate; and (iii) the presence of other evidence or alternative interpretations of the evidence.  
In addition, the ERG identified areas requiring clarification, for which the company provided additional 
evidence.  
 
 
3.1 Clinical Effectiveness Evidence Submitted by the Company 
The FRPSDQ\¶V VXEPLVVLRQ [3;18] included a systematic review and network meta-analysis (NMA) of the 
clinical effectiveness evidence. The aim of the review was to demonstrate the efficacy and safety of 
vedolizumab for the treatment of adult patients with moderate-to-severe active UC who are intolerant of, or 
whose disease has had an inadequate response or loss of response to conventional therapy (immunosuppressants 
and/or corticosteroids) or a TNF-ĮLQKLELWRU compared with established clinical treatment without vedolizumab.   
The GEMINI1 trial [19] (ClinicalTrials.gov identifier NCT00783718), which forms the main supporting 
evidence for the intervention, was a Phase III, multicentre (34 countries including 2 sites in the UK), 
randomised, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of vedolizumab 
as an induction treatment (Weeks 0 to 6) and maintenance treatment (Weeks 7 to 52) in patients with moderate-
to-severe active UC who had an inadequate response to, loss of response to, or intolerance of conventional 
therapy or TNF-Į inhibitor. 
 
In the 6-week induction phase, 374 patients were randomised (3:2 ratio) to receive 300mg vedolizumab 
intravenous (i.v.) or placebo (as saline) at Weeks 0 and 2, with two stratification factors: (1) concomitant use or 
non-use of glucocorticoids and (2) by concomitant use or non-use of immunosuppressive agents or prior use or 
non-use of anti-TNF-Į DJHQWV.  In order to fulfil sample size requirements for the maintenance study, an 
additional 521 patients were enrolled in an open-label group, who received the same treatment regime.  The 
primary endpoint was clinical response at week 6 (defined as a reduction in the Mayo Clinic score of at least 3 
points and a decrease of at least 30% from the baseline score, with a decrease of at least 1 point on the rectal 
EOHHGLQJVXEVFDOHRUDQDEVROXWHUHFWDOEOHHGLQJVFRUHRI).  In the double-blinded cohort, patients treated with 
vedolizumab had significantly higher rates of clinical response, clinical remission and mucosal healing 
compared with placebo (Table 1).  Additional post-hoc subgroup analyses showed that compared with placebo, 
treatment with vedolizumab improved clinical response and remission rates at 6-weeks in patients with no prior 
anti-TNF-ĮH[SRVXUH, and to a lesser extent in those with prior anti-TNF-ĮIDLOXUHp-values were not provided 
as the company VWDWHG WKDW µPXOWLSOH WHVWLQJ DGMXVWPHQWV ZHUH QRW PDGH¶  A post-hoc µGHOD\HG UHVSRQGHU¶
exploratory analysis in patients who failed to demonstrate clinical response at Week 6 in the induction phase 
found that the percentage of patients achieving clinical response (using partial Mayo scores) at Week 10 and 
Week 14 in vedolizumab-treated patients was 32% (102/322) and 39% (126/322), respectively, compared with 
placebo (15% (12/82) and 21% (17/82), respectively).    
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Table 1: Efficacy endpoints at week 6 in induction phase of GEMINI1 trial [19]  
Endpoint Vedolizumab 
300mg i.v. at 
weeks 0 and 2 
Placebo  Percentage difference 
(95% CI) 
p-value 
Double blinded cohort n=225 n=149   
Clinical responsea, No. (%) 
(primary end point) 
106 (47.1) 38 (25.5) 21.7 (11.6 to 31.7) <0.001 
Clinical remissionb, No. (%) 38 (16.9) 8 (5.4) 11.5 (4.7 to 18.3) 0.001 
Mucosal healingc, No. (%) 
 
92 (40.9) 37 (24.8)  16.1 (6.4 to 25.9) 0.001 
Open-labelled cohort n=521    
Clinical responsea, No. (%) 
 
231 (44.3)   NR 
No prior anti-TNF-ĮQDLYH n=130 n=76   
Clinical responsea, No. (%) 69 (53.1) 20 (26.3) 26.8 (13.7 to 39.9) NR 
Clinical remissionb, No. (%) 30 (23.1) 5 (6.6) 16.5 (2.4 to 30.2) NR 
Mucosal healingc, No. (%) 
 
64 (49.2) 19 (25.0) 24.2 (11.2 to 37.2) NR 
Prior anti-TNF-ĮIDLOXUH n=82 n=63   
Clinical responsea, No. (%) 32 (39.0) 13 (20.6) 18.4 (3.9 to 32.9) NR 
Clinical remissionb, No. (%) 8 (9.8) 2 (3.2) 6.6  (-9.8 to 22.8) NR 
Mucosal healingc, No. (%) 25 (30.5) 13 (20.6) 9.9 (-4.3 to 24.0) NR 
CI - confidence interval; NR - not reported 
 
a
 &OLQLFDOUHVSRQVHLVGHILQHGDVUHGXFWLRQLQFRPSOHWH0D\RVFRUHRISRLQWVDQGIURPEDVHOLQH:HHNZLWKDQ
DFFRPSDQ\LQJGHFUHDVHLQUHFWDOEOHHGLQJVXEVFRUHRISRLQWRUDEVROXWHUHFWDOEOHHGLQJVXEVFRUHRISRLQW 
b
 Clinical remission LVGHILQHGDVFRPSOHWH0D\RVFRUHRISRLQWVDQGQRLQGLYLGXDOVXEVFRUH!SRLQW 
c
 0XFRVDOKHDOLQJLVGHILQHGDV0D\RHQGRVFRSLFVXEVFRUHRISRLQW 
 
 
Patients with a clinical response at Week 6 from both the blinded and non-blinded cohort (n=373) were 
randomised (1:1:1 ratio) in the maintenance phase to a double-blind treatment with vedolizumab 300mg i.v. 
every 8 weeks (with placebo administered every other visit to preserve blinding), vedolizumab 300mg i.v. every 
4 weeks or placebo every 4 weeks for up to 52 weeks. The primary endpoint was clinical remission at 52 weeks 
(defined as D 0D\R VFRUH  SRLQWV ZLWK QR LQGLYLGXDO VFRUH !.  According to the cRPSDQ\¶V VXEPLVVLRQ, 
randomisation was stratified by three factors: (1) cohort; (2) concomitant use or non-use of glucocorticoids; and 
(3) concomitant use or non-use of immunosuppressive agents or prior use or non-use of anti-TNF-Į Patients in 
the induction study who did not have a clinical response at Week 6 continued to receive their assigned study 
drug (vedolizumab or placebo) every 4 weeks and were followed through until Week 52 separately from the 
maintenance study.  
 
In the maintenance phase higher rates of efficacy were observed in both the vedolizumab (300mg i.v.)  4-weekly 
and 8-weekly groups compared with the placebo group at Week 52 (Table 2).  In addition, no clear differences 
in efficacy were observed between the two vedolizumab regimens.  
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Table 2: Efficacy endpoints in maintenance phase of GEMINI1 trial [19] 
Study Endpoint Vedolizumab  
every 8weeks 
Vedolizumab  
every 4weeks 
 
Placebo 
 
Between group percentage differenceg 
Vedolizumab every 
8weeks vs placebo 
(95% CI) 
p-value Vedolizumab every 
4weeks vs placebo 
(95% CI) 
p-value 
ITT patientsa n=122 n=125 n=126     
Clinical remissionb at Wk, 52, No. (%) 51 (41.8) 56 (44.8) 20 (15.9) 26.1 (14.9 to 37.2) <0.001 29.1 (17.9 to 40.4) <0.001 
Durable clinical responsec, No. (%) 69 (56.6) 65 (52.0) 30 (23.8) 32.8 (20.8 to 44.7) <0.001 28.5 (16.7 to 40.3) <0.001 
Durable clinical remissiond, No. (%) 25 (20.5) 30 (24.0) 11 (8.7) 11.8 (3.1 to 20.5) 0.008 15.3 (6.2 to 24.4) 0.001 
Mucosal healing at Wk 52e, No. (%) 63 (51.6) 70 (56.0) 25 (19.8) 32.0 (20.3 to 43.8) <0.001 36.3 (24.4 to 48.3) <0.001 
Corticosteroid-free clinical remission at Wk 52f, No. 
(%)  
22/70 (31.4) 33/73 (45.2) 10/72 
(13.9) 
17.6 (3.9 to 31.3) 0.01 31.4 (16.6 to 46.2) <0.001 
 
Anti-TNF-ĮQDwYH n=72 n=73 n=79     
Clinical remissionb, No. (%) 33 (45.8) 35 (47.9) 15 (19.0) 26.8 (12.4 to 41.2) NRh 29.0 (14.6 to 43.3) NRh 
Durable clinical responsec, No. (%) 47 (65.3) 41 (56.2) 21 (26.6) 38.7 (24.0 to 53.4) NRh 29.6 (14.6 to 44.6) NRh 
Durable clinical remissiond, No. (%)  16 (22.2) 21 (28.8) 10 (12.7) 9.6 (-2.5 to 21.6) NRh 16.1 (3.4 to 28.8) NRh 
Mucosal healinge, No. (%) 43 (59.7) 44 (60.3) 19 (24.1) 35.7 (20.9 to 50.4) NRh 36.2 (21.6 to 50.9) NRh 
 
Prior Anti-TNF-ĮIDLOXUHSDWLHQWV n=43 n=40 n=38     
Clinical remissionb, No. (%) 16 (37.2) 14 (35.0) 2 (5.3) 31.9 (10.3 to 51.4) NRh 29.7 (7.4 to 49.4) NRh 
Durable clinical responsec, No. (%) 20 (46.5) 17 (42.5) 6 (15.8) 30.7 (11.8 to 49.6) NRh 26.7 (7.5 to 45.9) NRh 
Durable clinical remissiond, No. (%)  9 (20.9) 5 (12.5) 1 (2.6) 18.3 (-3.8 to 38.9) NRh 9.9 (-13.0 to 31.5) NRh 
Mucosal healinge, No. (%) 18 (41.9) 19 (47.5) 3 (7.9) 34.0 (12.6 to 53.2) NRh 39.6 (18.1 to 58.5) NRh 
CI - confidence interval; NR - not reported; ITT, intention-to-treat; Wk - week 
 
a
 Patients with insufficient diary entries were imputed as not achieving clinical response 
b &OLQLFDOUHPLVVLRQLVGHILQHGDVFRPSOHWH0D\RVFRUHRISRLQWVDQGQRLQGLYLGXDOVXEVFRUH!SRLQWDW:HHN 
c 'XUDEOHFOLQLFDOUHVSRQVHLVGHILQHGDVUHGXFWLRQLQFRPSOHWH0D\RVFRUHRISRLQWVDQGIURPEDVHOLQH:HHNZLWKDQDFFRPSDQ\LQJGHFUHDVHLQUHFWDOEOHHGLQJVXEVFRUHRISRLQWRUDEVROXWHUHFWDO
EOHHGLQJVXEVFRUHRISRLQWDWERWK:HHNVand 52. 
d 'XUDEOHFOLQLFDOUHPLVVLRQLVGHILQHGDVFRPSOHWH0D\RVFRUHRISRLQWVDQGQRLQGLYLGXDOVXEVFRUH!SRLQWDWERWK:HHNV6 and 52. 
e
 0XFRVDOKHDOLQJLVGHILQHGDV0D\RHQGRVFRSLFVXEVFRUHRISRLQW 
f Corticosteroid-free clinical remission is defined as patients using oral corticosteroids at baseline (Week 0) who have discontinued corticosteroids and are in clinical remission at Week 52. 
g
 Between-group differences in percentage points were adjusted for three stratification factors: cohort, concomitant use or non-use of glucocorticoids, and concomitant use or non-use of immunosuppressive agents or 
prior use or non-use of TNF-ĮDQWDJRQLVWV 
h
 p-values are not provided because multiple testing adjustments were not made. 
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Clinical response and remission rates were generally favourable for vedolizumab compared with placebo in both 
the anti-TNF-ĮQDwYHDQGDQWL-TNF-ĮIDLOXUHVXEJURXSV+RZHYHUHIILFDF\ZDVJUHDWHULQ the anti-TNF-ĮQDwYH
group compared with the anti-TNF-Įfailure group (see Table 2). In addition, a greater health-related quality of 
life (HRQoL) improvement was observed in patients treated with vedolizumab in both the induction and 
maintenance phase compared with the placebo group. 
 
In general, all efficacy analyses in the GEMINI1 trial [19] were conducted according to the intention-to-treat 
(ITT) principle whereby patients who withdrew prematurely were considered as treatment failures. In the 
induction phase, 6% (57/895) of the total population prematurely discontinued from the study. In contrast, a 
larger proportion of patients discontinued during the maintenance phase (44% (164/373) of the total population 
i.e. responders to vedolizumab during the induction phase that were re-randomised to maintenance therapy at 
Week 6). The main reasons for discontinuation in the vedolizumab and placebo groups were lack of efficacy or 
disease-related adverse events (AEs).   
 
The frequency of AEs was similar between the vedolizumab and placebo groups in the GEMINI1 trial [19].  The 
most commonly occurring AEs during the maintenance phase in the combined vedolizumab group compared 
with the combined placebo group were nasopharyngitis (12.9% versus 9.5%), headache (12.9% versus 10.2%), 
arthralgia (9.0% versus 9.1%) and upper respiratory tract infections (8.4% versus 7.6%), respectively. The 
majority of infusion-related reactions in the induction and maintenance phases were mild to moderate in severity 
with only 3 cases resulting in drug discontinuation. Although no cases of anaphylaxis, serum sickness or 
progressive multifocal leukoencephalopathy (PML) were observed, one patient died during the GEMINI1 trial 
[19]; this was considered by the study investigators to be unrelated to treatment. Supplementary safety evidence 
from an ongoing GEMINI Long Term Safety trial (LTS) [20;21]  (ClinicalTrials.gov identifier NCT00619489) 
and two separate pooled safety analyses (not meta-analysed) were also provided by the company [22;23].  In 
JHQHUDOWKHRYHUDOOVDIHW\SURILOHRIYHGROL]XPDEDSSHDUHGWREHVLPLODUEHWZHHQSDWLHQWVZLWK8&DQG&URKQ¶V
disease (CD) with slightly higher rates of AEs in the CD patients. As of June 2013, no cases of PML had been 
reported in any of the >2,700 patients treated with vedolizumab, including approximately 900 patLHQWVZLWK
months exposure.  In addition, a total of 26 vedolizumab-treated patients in the integrated safety population had 
been diagnosed with malignancy, of which 18 met serious adverse event (SAE) criteria. Tuberculosis (TB) was 
reported in a total of 4 patients (3 with CD, 1 with UC), and 13 deaths occurred across all controlled and 
uncontrolled studies in UC (n=4) and CD (n=9). None of the UC deaths were considered by the study 
investigators to be treatment-related.  
 
In the absence of any direct head-to-head randomised controlled trials (RCTs) comparing vedolizumab and 
other relevant biologic therapies for the treatment of moderate-to-severe UC, the company conducted an NMA. 
The NMA compared vedolizumab, adalimumab, golimumab, infliximab and placebo for the outcomes; clinical 
response, durable clinical response, clinical remission, mucosal healing, discontinuation due to AEs, SAEs and 
corticosteroid-free (CSF) remission using data from the trials: GEMINI1 (vedolizumab) [19],  ULTRA1 
(adalimumab) [24],  ULTRA2 (adalimumab) [25], ACT1 (infliximab) [26], ACT2 (infliximab) [26], PURSUIT-
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SC (golimumab) [27], PURSUIT-M (golimumab) [28] and Suzuki 2014 (adalimumab) [29].  The size of the 
network for each outcome varied depending on the availability of the data in each study.  
 
The fixed effects NMA suggested that in the induction phase for anti-TNF-ĮQDwYHSDWLHQWVLQIOL[LPDESURYLGHG
the largest treatment effect on clinical response, remission and mucosal healing compared with placebo, and 
vedolizumab was associated with the lowest rate of discontinuations due to AEs compared with placebo. In the 
induction phase for patients who had previously had TNF-Į inhibitors, only the treatment effects of adalimumab 
and vedolizumab were analysed relative to placebo. Each had positive effects in term of clinical response, 
remission and mucosal healing, but only the effect of vedolizumab compared with placebo for the outcome of 
response was statistically significant. For the maintenance phase, vedolizumab was associated with the largest 
treatment effect compared with placebo in both the anti-TNF-ĮQDwYHDQGDQWL-TNF-ĮIDLOXUHSDWLHQWVXEJURXSV 
However, only those patients who responded to vedolizumab in the induction phase entered the GEMINI1 [19] 
maintenance phase hence there is no data available to compare the effect/efficacy of vedolizumab against 
placebo in the maintenance phase in patients who responded to placebo in the induction phase. 
 
3.1.1. Critique of Clinical Effectiveness Evidence and Interpretation 
The systematic review process followed by the company was comprehensive. Despite minor limitations in the 
company¶Vsearch strategy, the ERG was confident that all relevant studies of vedolizumab were included in the 
FRPSDQ\¶VVXEPLVVLRQ. The specified inclusion and exclusion criteria appeared generally appropriate and reflect 
the information given in the decision problem. The validity assessment tool used to appraise the included 
studies, as suggested by NICE [30], was based on the quality assessment criteria for RCTs and was considered 
appropriate by the ERG. 
 
Although the efficacy and safety of vedolizumab was positively demonstrated (compared with placebo) in the 
GEMINI1 study [19], there were a number of limitations and uncertainties which warrant caution in the 
interpretation of the available evidence. Owing to the high discontinuation rates in the maintenance phase of the 
GEMINI1 trial [19], estimates of treatment effects (including magnitude) may be confounded. The subgroup 
analyses undertaken to determine the efficacy of vedolizumab in patients who were anti-TNF-ĮIDLOXUHDQGLQ
patients who were anti-TNF-ĮQDwYHZHUHH[SORUDWRU\DQGWKHVWXG\ZDVQRWSRZHUHGIRUWhese assessments. The 
duration of treatment of vedolizumab in the GEMINI1 trial [19] was 52 weeks, followed by enrolment in the 
ongoing GEMINI LTS study [20;21].  As a result, the long-term efficacy and safety of vedolizumab is unknown 
and the optimum duration of therapy remains unclear. There are no data on strategies for withdrawal of the drug 
in those on maintenance therapy or how to predict instances in which this can be successfully achieved. 
Furthermore, the safety and efficacy of vedolizumab has not been established in children aged below 17 years, 
in pregnant women, in women of childbearing potential, lactating mothers, patients with renal or hepatic 
impairment, or in concomitant use with biologic immunosuppressants.  Finally, of the 211 study sites from 
which patients were recruited, only two were UK-based and 63 were US-based. With the exception of the US 
sites, where permitted immunosuppressants were discontinued after induction, all other sites maintained 
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immunosuppressants at stable doses throughout the induction and maintenance period.  As such, there is some 
uncertainty regarding the generalisability of the evidence to the clinical population of England and Wales. 
 
Despite considerable differences between the trials included in the NMA, WKHFRPSDQ\¶V10$XVHGD IL[HG-
effect model.  As a result, the ERG believes that the results presented may have underestimated the uncertainty 
in treatment effects.  Moreover, the main differences between the studies in both the induction phase and 
maintenance phase related to the following: patient characteristics, study design (randomisation at baseline or 
re-randomisation of biologic induction-responders) and study duration.  Only GEMINI1 [19] and ULTRA2 [25] 
included patients with prior anti-TNF-Į H[SHULHQFH and anti-TNF-Į QDwYH SDWLHQWV ZKLOVW $&7 [26], ACT2 
[26], PURSUIT-SC [27], Suzuki 2014 [29] and ULTRA1 [24] included only patients who were anti-TNF-Į
naïve. Within PURSUIT-M [28], all recruited patients were golimumab induction-responders [27].  It is 
noteworthy, that patients with prior anti-TNF-ĮH[SHULHQFH may be a more difficult to treat population than those 
who are anti-TNF-Į QDwYH  Furthermore, the inclusion criteria between GEMINI1 [19] and ULTRA2 [25] 
differed.  In GEMINI1 [19], failure to anti-TNFs was defined as inadequate response (i.e. primary non-
responders to induction therapy with anti-TNF therapy), loss of response (i.e. secondary non-response/loss of 
response to anti-TNFs over time following initial response) or patients were intolerable to anti-TNFs. Whereas  
ULTRA2 [25] included people whose disease had lost response to, or who could not tolerate another anti-TNF, 
before starting adalimumab (i.e. this study does not appear to have included primary non-responders to anti-
TNFs).  In terms of study design, the adjustments made by the company in the maintenance phase to the trials 
without re-randomisation at the end of the induction phase inflate estimates of treatment effects in both the 
placebo and experimental treatment groups. The impact of this adjustment on the relative treatment effect in 
these trials was not clear.  It was also unclear if the large relative treatment effect observed for vedolizumab 
compared with placebo in the GEMINI1 [19] maintenance phase was due to the low event rates for placebo, 
which included only prior vedolizumab induction-responders.  Whilst the placebo arm in ULTRA2 [25] 
maintenance phase included both induction-responders and non-responders as patients were randomised to 
induction and maintenance regimes at baseline.  Hence, it was not clear if the placebo groups in these two trials 
[19;25] are comparable in the NMA for the anti-TNF-Į IDLOXUH/experience subgroup. The anti-TNF-Į QDwYH
subgroup also has this comparability issue in the maintenance phase. The results of the NMA for clinical 
response and remission should be interpreted with further caution because these were estimated without 
considering the dependence/correlation between response and remission i.e. remission is a subset of response 
and the data are ordered categorical in nature, but the NMA was binary and considered only response or no 
response, or remission or no remission. Use of these results in the economic model ignores this dependence and 
may generate inappropriate samples for probabilistic sensitivity analysis (PSA). 
 
 
3.2 Cost-Effectiveness Evidence Submitted by the Company  
The company submitted a model-based cost-utility analysis as part of their submission [3;18]. The analysis was 
undertaken from the perspective of the NHS over a 10-year time horizon. The company¶VDQDO\VLVwas presented 
for three populations: (1) the mixed ITT population, which is comprised of patients who have previously 
received anti-TNF-ĮWKHUDS\DQGWKRVHZKRDUHDQWL-TNF-ĮQDwYHSDWLHQWVZKRDUHDQWL-TNF-ĮQDwYHRQO\
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and; (3) patients who have previously failed anti-TNF-Į WKHUDS\RQO\:LWKLQ all three analyses, comparators 
included conventional non-biologic therapies (a combination of 5-aminosalicylic acids, immunomodulators and 
corticosteroids) and surgery as separate options. Other anti-TNF-Į DJHQWV LQIOL[LPDE DGDOLPXPDE DQG
golimumab) were included only in the analysis of the anti-TNF-Į QDwYH SRSXODWLRQ &DOFLQHXULQ LQKLELWRUV
(tacrolimus and ciclosporin) were not included in the economic analysis. All analyses included price reductions 
to reflect the proposed Patient Access Scheme (PAS) for vedolizumab. 7KHFRPSDQ\¶VPRGHODGRSWHGDK\EULG
approach whereby a decision tree was used to evaluate outcomes at the end of induction therapy and a Markov 
structure was used to evaluate subsequent maintenance treatment outcomes (including subsequent induction 
treatment using conventional therapies for patients who discontinue biologic treatments). Pre-colectomy health 
states were defined according to Mayo score (remission, mild, moderate-to-severe UC); additional states were 
included to reflect surgery, post-surgical complications and post-surgical remission and death.  
 
The company¶V UHVXOWV ZHUH SUHVHQWHG DV SDLUZLVH FRPSDULVRQV RI YHGROL]XPDE YHUVXV HDFK FRPSDUDWRU DQG
were thus difficult to interpret appropriately. Based on a fully incremental analysis of all treatment options 
undertaken by the ERG (see Table 3), within the mixed ITT population, the company¶V PRGHO VXJJHVWV WKDW
surgery is dominated as it produces fewer health gains and is more costly than both conventional therapy and 
vedolizumab. Vedolizumab is expected to be the most effective option. Compared with conventional therapy, 
vedolizumab is expected to produce an additional 0.15 quality adjusted life years (QALYs) at an incremental 
cost of £5,131; the incremental cost-effectiveness ratio (ICER) for vedolizumab versus conventional therapy is 
estimated to be £33,297 per QALY gained. Within the anti-TNF-ĮQDwYHSRSXODWLRQVXUJHU\LVH[SHFWHGWREH
dominated by medical therapies. Vedolizumab is expected to be the most effective option. Infliximab and 
golimumab are expected to be dominated by vedolizumab. The ICER for adalimumab versus conventional 
therapy is estimated to be £3,664 per QALY gained, whilst the ICER for vedolizumab versus adalimumab is 
estimated to be £6,634 per QALY gained. Within the anti-TNF-ĮIDLOXUHSRSXODWLRQsurgery is expected to be 
dominated. Vedolizumab is expected to be the most effective option. Compared with conventional therapy, 
vedolizumab is expected to produce an additional 0.09 QALYs at an incremental cost of £5,839; the ICER for 
vedolizumab versus conventional therapy is estimated to be £64,999 per QALY gained. 
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Table 3&RPSDQ\¶VFRVW-effectiveness results 
Option QALYs Costs Incremental 
QALYs 
Incremental 
costs 
Pairwise 
ICER 
(vedolizumab 
versus 
comparator) 
Mixed ITT population 
Vedolizumab 5.55 £77,056 - - - 
Conventional therapy 5.40 £71,925 0.15 £5,131 £33,297 
Surgery 4.28 £107,831 1.27 -£30,775 dominating 
Anti-TNF-ĮQDwYHSRSXODWLRQ 
Vedolizumab 5.90 £69,075 - - - 
Infliximab 5.82 £73,952 0.08 -£4,877 dominating 
Golimumab 5.79 £70,387 0.11 -£1,312 dominating 
Adalimumab 5.76 £68,157 0.14 £918 £6,634 
Conventional therapy 5.56 £67,406 0.34 £1,669 £4,862 
Surgery 4.28 £107,831 1.67 -£38,756 dominating 
Anti-TNF-ĮIDLOXUHSRSXODWLRQ 
Vedolizumab 5.46 £78,409 - - - 
Conventional therapy 5.37 £72,570 0.09 £5,839 £64,999 
Surgery 4.28 £107,831 1.182 -£29,422 dominating 
 
 
 
3.2.1 Critique of Cost-Effectiveness Evidence and Interpretation 
The ERG critically appraised the company¶VKHDOWKHFRQRPLFDQDO\VLVDQGWKHPRGHOXSRQZKLFKWKLVDQDO\VLV
was based.  
The ERG partially re-built part of the model to check for technical programming errors; one serious 
programming error was found; in the anti-TNF-Į QDwYH SRSXODWLRQ WKH PDLQWHQDQFH WUDQVLWLRQ PDWUL[ IRU
conventional therapy incorrectly draws on the transition matrix for infliximab. Fixing this error, however, did 
not have a significant impact on the results. The broader critical appraisal of the company¶VPRGHOKLJKOLJKWHGD
number of concerns and uncertainties. The most notable of these related to (i) the deviations from the NICE 
Reference Case [31] and final NICE scope [17]; (ii) questionable assumptions regarding 
continuation/discontinuation of vedolizumab and other biologic therapies; (iii) highly pessimistic assumptions 
regarding the use, costs and benefits of colectomy, and; (iv) considerable uncertainty regarding the methods 
used to calibrate and extrapolate the pre-colectomy maintenance transition matrices.  
 
(i) Deviations from the NICE Reference Case 
TKHFRPSDQ\¶VHFRQRPLFDQDO\VLVGHYLDWHGIURPWKH1,&(5HIHUHQFH&DVH [31] and the final NICE scope [17] 
due to (a) missing biologic comparators in the mixed ITT population and the anti-TNF-ĮIDLOXUHSRSXODWLRQVE
the use of a 10-year (rather than lifetime) time horizon and (c) the use of pairwise comparisons rather than a 
IXOO\LQFUHPHQWDODQDO\VLV7KHVHLVVXHVKLQGHUHGWKHLQWHUSUHWDWLRQRIWKHFRPSDQ\¶VUHVXOWVDJDLQVWWKHGHFLVLRQ
problem specific in the NICE scope [17]. Whilst the ERG was able to re-DQDO\VHWKHFRPSDQ\¶VUHVXOWVXVLQJD
fully incremental framework over a lifetime horizon, it was not possible to address issues surrounding missing 
comparators. 
13 
 
(ii) Questionable assumptions regarding continuation/discontinuation of vedolizumab and other biologic 
therapies 
7KHFRPSDQ\¶VKHDOWKHFRQRPLFmodel assumed that all patients who are still receiving anti-TNF-ĮWKHUDS\DW-
year will discontinue and subsequently receive non-biologic therapies, irrespective of whether they are currently 
responding to treatment. Whilst there is uncertainty with respect to the long-term efficacy of vedolizumab, 
infliximab, adalimumab and golimumab as the randomised phases of trials of these therapies adopted a 
maximum follow-up of 54 weeks, the wording of the marketing authorisations for the biologics does not 
stipulate if or when responding patients should discontinue therapy [16;32-35].  The ERG had concerns that the 
discontinuation rXOHDGRSWHGLQWKHFRPSDQ\¶VPRGHOZRXOGQRWEHDGKHUHGWRLQURXWLQHSUDFWLFHDVLWPD\QRW
be preferable to patients and clinicians to withdraw biologic therapy when a patient is still obtaining clinical 
benefit from it. 
 
(iii) Pessimistic assumptions regarding the use, costs and benefits of colectomy 
A number of assumptions used in the calculation of the surgery and post-surgery health states were likely to bias 
against surgery and towards medical interventions by overestimating the costs and reducing the health gains of 
surgery. The surgery health state represents a patient undergoing a colectomy and any further routine surgery 
associated with the procedure. By returning patients to the surgery health state, to reflect that a proportion of 
patients undergo further unplanned surgeries, the model assumed these patients undergo a further colectomy and 
all associated surgeries. In total the model assumed that over a 10 year period a patient would cycle through the 
surgery health state 4.3 times and over a lifetime horizon would cycle through the surgery health state up to 19 
times. The model was also likely to have overestimated the rate of post-surgical complications. Data from the 
literature on rates of complications up to 30 days and up to six months following surgery were converted to 
constant transition probabilities [36;37]. These may have overestimated the long term probabilities of 
complications as the likelihood of complications decreases as the time from surgery increases [38;39]. The 
health utilities used were also likely to bias against surgery as the utility for post-surgical remission is lower 
than that for moderate-to-severe UC indicating that it would be illogical for any patient to opt for surgery.  
  
(iv) Uncertainty surrounding pre-colectomy maintenance transition matrices 
The method for deriving the pre-colectomy transition matrices adopted by the company was unconventional. 
7KH FRPSDQ\¶V PRGHO XVHd the Microsoft Excel Solver add-in to determine pre-colectomy transition 
probabilities (response, remission and active UC) by comparing the model-predicted proportion of patients in 
remission or response at 1-year against the observed proportion of patients in remission or response at 1-year in 
GEMINI1 [19], or against the predicted proportion bDVHG RQ WKH PDQXIDFWXUHU¶V 10$V RI LQGXFWLRQ DQG
maintenance therapies (note - the target datapoints and their derivation depend on the population considered in 
the analysis). The ERG had concerns that (i) the FRPSDQ\¶V calibration approach discarded the empirical 
GEMINI1 trial data [19] that could have been used to directly estimate transition probabilities; (ii) the initial 
starting matrix of transitions used in the optimisation approach appeared to be largely arbitrary; (iii) the 
constraints imposed in the optimisation approach appeared to be largely arbitrary (for example, no more than 
99.5% of patients remain in remission over each 8-week cycle); (iv) fitting seven unknown parameters to two 
known datapoints is likely to result in overfitting and many combinations of transition probabilities could have 
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fitted the two target datapoints, and; (v) the fitting process ignored those patients who achieved response but had 
moderate-to-severe disease.  This issue could have been better addressed by using the observed transitions 
between moderate-to-severe UC, response and remission states using the individual patient data from the 
GEMINI1 trial [19]. The ERG requested but did not receive these data from the company.  
 
 
3.3 Additional work undertaken by the Evidence Review Group 
In light of the problems identified during the critical appraisal, the ERG undertook a number of additional 
analyses to explore the impact of likely biases on the cost-effectiveness of vedolizumab. Nine sets of additional 
analyses were undertaken in each of the three modelled populations; these included correcting the mistake in the 
maintenance transition matrix for conventional management in the anti-TNF-Į QDwYH SRSXODWLRQ WKH XVH RI
alternative sources of HRQoL values i.e. using utilities for patients with UC in various health states (remission, 
response, moderate-to-severe UC and post-surgery), based on data  reported by Woehl et al. [40] and Swinburn 
et al. [39], amending the surgery and post-surgical transition probabilities to better reflect clinical reality, 
removing assumptions regarding biologic treatment discontinuation, removing assumptions regarding the lower 
use of conventional therapies whilst patients are also receiving biologics, and improving the cost estimates used 
in the model to better reflect the costs borne by the NHS. The ERG also produced a preferred base case which 
combines most of these additional analyses. The results of these additional analyses did not consistently favour 
one particular option but indicated that these issues have the propensity to dramatically shift the ICER for 
vedolizumab versus other therapies in all three populations. The ERG-preferred base case indicated that surgery 
was likely to dominate all medical treatments in all three populations analysed. However, surgery may not be an 
acceptable option for all patients. Where surgery is not an acceptable option in the mixed ITT population, the 
ICER for vedolizumab versus conventional therapy was estimated to be £53,084 per QALY gained. Where 
surgery was not an acceptable option in the anti-TNF-Į QDwYH SRSXODWLRQ YHGROL]XPDE LV H[SHFWHG WR EH
dominated by adalimumab. Where surgery is not an acceptable option in the anti-TNF-ĮIDLOXUe population, the 
ICER for vedolizumab versus conventional therapy was estimated to be £48,205 per QALY gained. 
 
3.4 Conclusion of the Evidence Review Group Report 
On the basis of the evidence submitted by the company, the ERG concluded that vedolizumab was clinically 
more effective than placebo for the treatment of moderate-to-severe active UC, in patients who had an 
inadequate response to, loss of response to, or intolerance of conventional therapy or TNF-Į.  However, there 
are a number of limitations and uncertainties in the evidence base which warrant caution in its interpretation. In 
addition, the results presented in the NMA may have underestimated the uncertainty in treatment effects.  
The ERG believed that robust estimates of the likely cost-effectiveness of vedolizumab could not be made on 
WKH EDVLV RI WKH RULJLQDO YHUVLRQ RI WKH FRPSDQ\¶V HFRQRPLF PRGHO  +RZHYHU RQ WKH EDVLV RI WKH (5*¶V
DPHQGHGYHUVLRQRIWKHFRPSDQ\¶VPRGHOEDVHGRQOLIHWLPHKRUL]RQLQFOXGLQJWKHUHYLVHGSDWLHQWDFFHVVVFKHPH, 
surgery was more effective and less costly than vedolizumab. In the whole population, the ICER for 
vedolizumab compared with conventional therapy was £53,084 per QALY gained.  In the population who have 
not had prior treatment with TNF-Į inhibitors, vedolizumab is dominated by adalimumab.  In the population in 
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whom treatment with a prior TNF-Įinhibitor has failed, the ICER for vedolizumab compared with conventional 
therapy is £48,205 per QALY gained. 
 
4. Key Methodological Issues 
Several methodological issues in the cost-effectiveness evidence and uncertainties in the clinical effectiveness of 
vedolizumab were highlighted during the appraisal. The subgroup analyses to determine the efficacy of 
vedolizumab in patients with prior TNF-Įinhibitor failure and in patients who were TNF-Įinhibitor naïve were 
exploratory and the study was not powered for these assessments.   Furthermore, there are no data on strategies 
for withdrawal of the drug or optimum duration and the trial was not large enough or of sufficient duration to 
estimate the risk of uncommon AEs.  
 
The ERG considered that the results of the NMA may underestimate the uncertainty in treatment effects since 
fixed effects models were used, and there was clear evidence of heterogeneity among the trials included. There 
are also issues regarding the adjustment of data to account for re-randomisation which may lead to bias in the 
PRGHO¶VUHVXOWV 
The health economic model submitted by the company was subject to a number of issues which limited the 
credibility of the company¶V UHVXOWV 7KHVH LQFOXGH HUURUV LQ PRGHO LPSOHPHQWDWLRQ WKH RPLVVLRQ RI UHOHYDQW
comparators, deviations from the NICE Reference Case and questionable model assumptions. Whilst the 
company¶VHFRQRPLFDQDO\VLVVXJJHVWVWKDWWKH,&(5IRUYHGROL]XPDELVEHORZSHU4$/<JDLQHGZLWKLQ
the anti-TNF-Į QDwYH SRSXODWLRQ WKH (5*-preferred base case indicates that vedolizumab is expected to be 
dominated by surgery in all three populations 
 
 
5.  National Institute for Health and Care Excellence Guidance 
The Appraisal Committee reviewed the data available on the clinical and cost-effectiveness of vedolizumab, 
having considered evidence on the nature of moderate-to-severe active UC and the value placed on the benefits 
of vedolizumab by people with the condition, those who represent them, and clinical experts. It also took into 
account the effective use of NHS resources. In November 2014, the Appraisal Committee produced preliminary 
recommendation, recorded in the ACD, which stated the following: 
Vedolizumab is recommended within its marketing authorisation as an option for treating moderately to 
severely active UC in adults only if: the person has not had a TNF-Į inhibitor or the person has had a TNF-Į 
inhibitor but could not tolerate it and the company provides vedolizumab with the discount agreed in the patient 
access scheme.  However, vedolizumab is not recommended for treating moderately to severely active UC in 
people who have not had a response to, or have lost response to, treatment with a TNF-Į inhibitor.  People 
currently having treatment initiated within the NHS with vedolizumab that is not recommended for them by 
NICE, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.  
In response to the consultation, the company requested NICE to reconsider its preliminary recommendation 
regarding the use of vedolizumab in patients who have failed anti-TNF-Į inhibitor.  The company submitted 
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supportive evidence detailing the unmet need associated with anti-TNF-Į IDLOXUH the limited current options 
(high dose steroids, anti-TNF-Į cycling or surgery) available for this patient group, highlighted the clinical 
evidence from GEMINI1 trial [19], the limitations of the QALY approach in UC and submitted a revised cost-
effectiveness analysis using the ERG/NICE suggested base case parameters for the analysis of the anti-TNF-Į
failure population.   
 
Following further consultation, in June 2015, NICE issued its final guidance and recommended the use of 
vedolizumab within its marketing authorisation, as an option for treating moderately to severely active UC in 
adults who had an inadequate response to, loss of response to, or intolerance of conventional therapy or TNF-Į
inhibitor but only if the company provided vedolizumab with the discount agreed in the patient access scheme. 
Vedolizumab should be given until it stops working or surgery is needed. At 12 months after the start of 
treatment, people should be reassessed to see whether treatment should continue. Treatment should only 
continue if there is clear evidence of ongoing clinical benefit.  For people who are in complete remission at 12 
months, consideration should be given in stopping vedolizumab therapy.  However, if patients relapse, treatment 
should be resumed. People who continue vedolizumab should be reassessed at least every 12 months to see 
whether continued treatment is justified [41]. 
 
5.1 Consideration of Clinical and Cost-Effectiveness Issues  
This section discusses the key issues considered by the Appraisal Committee. The full list can be found in the 
$SSUDLVDO&RPPLWWHH¶V)$' [41]. 
 
5.1.1 Generalisability to the UK population 
The Committee considered the generalisability of the population in GEMINI1 to the population who would have 
received vedolizumab in clinical practice in England. It understood that GEMINI1 [19] was an international 
study and 2 of the centres were in the UK. It was aware that there were differences in the study entry criteria 
between the USA and other centres. These differences related to which previous treatments had failed and the 
use of immunosuppressants during the study. The Committee heard from the clinical experts that the population 
included in the trial broadly reflected the population who would be treated with vedolizumab in England. It also 
heard that differences in immunosuppressant use between trial centres were unlikely to affect the trial's 
generalisability to clinical practice in England. The Committee concluded that the clinical efficacy results from 
GEMINI1 [19] were generalisable to clinical practice, but that there was uncertainty about whether the 
proportion of people who had previous TNF-Į inhibitor treatment in GEMINI1 [19] would be the same as in the 
population considered for vedolizumab treatment in England. 
 
5.1.2 Estimate of the size of the clinical effectiveness 
The Committee discussed the efficacy estimates for vedolizumab from GEMINI1 [19]. The Committee noted 
that in GEMINI1 [19] people had vedolizumab at Weeks 0 and 2 and response was assessed at Week 6, but the 
marketing authorisation for vedolizumab states that people should have 3 doses before response is assessed at 
Week 10. The Committee concluded that, although the efficacy of vedolizumab had been shown in GEMINI1 
[19], it may have underestimated the proportion of people who would have a response to induction treatment in 
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clinical practice, and that data on the outcome for those who responded after 6 weeks were not available from 
the trial. 
 
5.1.3 Uncertainties generated by the evidence 
The Committee considered the NMA presented by the company to estimate the relative effectiveness of 
vedolizumab [19] compared with adalimumab [25], infliximab [26] and golimumab [27]. It noted that clinical 
data for infliximab [26] and golimumab [27] were not available for people who had previously had a TNF-Į 
inhibitor. Therefore, for this subgroup a comparison could only be made between vedolizumab [19] and 
adalimumab [25]. The Committee understood that the company had presented NMA for the subgroups rather 
than the whole population. The Committee noted the ERG's concerns that there were differences between the 
trials included in the meta-analyses, and the company had presented results from a fixed-effect model which was 
less suitable than a random-effects model in these circumstances. The Committee understood that a NMA for 
the whole population would include data from studies that included people who had, and had not, taken a TNF-Į
inhibitor, and that these differences in patient characteristics may affect the results. Therefore, the Committee 
recognised that the relative effectiveness of vedolizumab compared with the TNF-Įinhibitors, obtained from a 
mixed treatment comparison of the whole population, would be subject to considerable uncertainty. 
 
5.1.4 Uncertainties around plausibility of assumptions and inputs in the economic model 
The Committee discussed the uncertainty around cost and frequency of surgery.  The Committee noted that 
when the company's model was run over 10 years, people would have 4 operations, and over a lifetime time 
horizon up to 19 operations.  The ERG considered that the total number of operations, and therefore the costs 
was overestimated by the company.  The clinical experts highlighted that that surgery for UC was normally 
carried out in 3 stages in separate operations, and a person could have further surgery if there were 
complications or further problems.  The ERG considered the cost of surgery from Buchanan 2011 [42], which 
were used by the company and represented the total cost of multiple operations.  The clinical expert argued that 
the costs reported by Buchanan 2011 [42]  only accounted for the cost of one operation.  The Committee 
concluded that the total costs of surgery in the company's base case were too high due to the number of 
operations included and those in the ERG exploratory base case were too low. 
 
6. Appraisal CommitWHH¶V.H\&onclusion 
The Committee considered that taking into account the uncertainty of the utility values, and the costs of surgery 
and post-surgery care, the ICER of vedolizumab for people who had not had TNF-Įinhibitors before was well 
within the range normally considered to be cost-effective. It was concerned that the plausible ICERs for people 
in whom treatment with a TNF-Į inhibitor had failed were around the upper limit of the range normally 
considered to be a cost-effective use of NHS resources. The Committee recommended vedolizumab, within its 
marketing authorisation, as an option for treating moderately to severely active UC in adults only if the 
company provides vedolizumab with the discount agreed in the patient access scheme.  
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